Paty E, de Blic J, Brunet D, Le Bourgeois M, Garcelon M, Paupe J, Scheinmann P
Service d'Allergologie, Hôpital des Enfants-Malades, Paris.
Arch Fr Pediatr. 1990 Mar;47(3):173-9.
An homogeneous group of 17 children with severe chronic asthma were given a rush immunotherapy with standardized Dermatophagoides pteronyssinus extracts. Maintenance dose was injected monthly for one year. Symptom and medication scores as well as functional (lung function tests, specific nasal challenges), immunologic and allergic parameters (skin tests, total serum IgE, specific IgE and IgG4) were recorded before and at the end of the study. Rush immunotherapy was well tolerated in spite of some moderate systemic adverse reactions. Symptom and medication scores improved in 10 children. Nasal and skin sensitivity decreased in respectively 3 and 7 children. However there was no correlation between the improvement of quality of life and laboratory results. This study shows that specific immunotherapy is possible in children with severe asthma. Its efficacy should be assessed by symptom and medication scores.
对一组由17名重度慢性哮喘儿童组成的同质群体给予标准化屋尘螨提取物进行快速免疫疗法。维持剂量每月注射一次，持续一年。在研究开始前和结束时记录症状和药物评分以及功能（肺功能测试、特异性鼻腔激发试验）、免疫和过敏参数（皮肤试验、总血清IgE、特异性IgE和IgG4）。尽管出现了一些中度全身不良反应，但快速免疫疗法耐受性良好。10名儿童的症状和药物评分有所改善。分别有3名和7名儿童的鼻腔和皮肤敏感性降低。然而，生活质量的改善与实验室结果之间没有相关性。这项研究表明，重度哮喘儿童进行特异性免疫疗法是可行的。其疗效应通过症状和药物评分来评估。
